300 related articles for article (PubMed ID: 27334058)
1. The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.
Miura SI; Suematsu Y; Matsuo Y; Tomita S; Nakayama A; Goto M; Arimura T; Kuwano T; Yahiro E; Saku K
Hypertens Res; 2016 Nov; 39(11):758-763. PubMed ID: 27334058
[TBL] [Abstract][Full Text] [Related]
2. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
3. Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects.
Flarakos J; Du Y; Bedman T; Al-Share Q; Jordaan P; Chandra P; Albrecht D; Wang L; Gu H; Einolf HJ; Huskey SE; Mangold JB
Xenobiotica; 2016 Nov; 46(11):986-1000. PubMed ID: 26931777
[TBL] [Abstract][Full Text] [Related]
4. Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide.
Miura S; Nakayama A; Tomita S; Matsuo Y; Suematsu Y; Saku K
Clin Exp Hypertens; 2015; 37(5):353-7. PubMed ID: 25496380
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Vilela-Martin JF
Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196
[TBL] [Abstract][Full Text] [Related]
6. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
Mochel JP; Teng CH; Peyrou M; Giraudel J; Danhof M; Rigel DF
Eur J Pharm Sci; 2019 Feb; 128():103-111. PubMed ID: 30508581
[TBL] [Abstract][Full Text] [Related]
7. Sacubitril/Valsartan (LCZ696) in Heart Failure.
Khder Y; Shi V; McMurray JJV; Lefkowitz MP
Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
Marques da Silva P; Aguiar C
Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
[TBL] [Abstract][Full Text] [Related]
9. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
[TBL] [Abstract][Full Text] [Related]
10. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
Kusaka H; Sueta D; Koibuchi N; Hasegawa Y; Nakagawa T; Lin B; Ogawa H; Kim-Mitsuyama S
Am J Hypertens; 2015 Dec; 28(12):1409-17. PubMed ID: 25762811
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Chrysant SG
J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
Seki T; Goto K; Kansui Y; Ohtsubo T; Matsumura K; Kitazono T
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042424
[TBL] [Abstract][Full Text] [Related]
13. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
[TBL] [Abstract][Full Text] [Related]
14. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.
Langenickel TH; Tsubouchi C; Ayalasomayajula S; Pal P; Valentin MA; Hinder M; Jhee S; Gevorkyan H; Rajman I
Br J Clin Pharmacol; 2016 May; 81(5):878-90. PubMed ID: 26663387
[TBL] [Abstract][Full Text] [Related]
15. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
Lillyblad MP
Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
[TBL] [Abstract][Full Text] [Related]
16. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor.
Gan L; Langenickel T; Petruck J; Kode K; Rajman I; Chandra P; Zhou W; Rebello S; Sunkara G
J Clin Pharmacol; 2016 Jan; 56(1):78-86. PubMed ID: 26073563
[TBL] [Abstract][Full Text] [Related]
17. Long-term neprilysin inhibition - implications for ARNIs.
Campbell DJ
Nat Rev Cardiol; 2017 Mar; 14(3):171-186. PubMed ID: 27974807
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
Gori M; Volterrani M; Piepoli M; Senni M
Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
[TBL] [Abstract][Full Text] [Related]
20. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]